Sevelamer reduces endothelial inflammatory response to advanced glycation end products

BACKGROUND: Advanced glycation end products (AGEs) have been related to the pathogenesis of cardiovascular diseases (CVD), chronic kidney disease (CKD) and diabetes mellitus. We sought to investigate the binding capacity of sevelamer to both AGEs and uremic serum in vitro and then test this pharmace...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Kidney J
Autors principals: Gregório, Paulo C, Favretto, Giane, Sassaki, Guilherme L, Cunha, Regiane S, Becker-Finco, Alessandra, Pecoits-Filho, Roberto, Souza, Wesley M, Barreto, Fellype C, Stinghen, Andréa E M
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
CKD Complications
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5798142/
https://ncbi.nlm.nih.gov/pubmed/29423208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfx074
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars